Global Wilson’s Disease Market: Industry Analysis & Outlook (2016-2020) - New Report by Koncept Analytics

1
Global Wilsons Disease Market Industry
Analysis Outlook ------------------------------
---------- (2016-2020)
View Report Details
2
View Report Details

• Executive Summary
• Wilsons disease is a rare disease and is named
  after Kinnear Wilson who was the first to
  describe this disorder in 1912. His description
  terms the disease as a progressive lenticular
  degeneration, a hereditary, fatal neurological
  disease that is usually accompanied by chronic
  liver ailment that leads to a condition called
  cirrhosis. Wilson's disease is a hereditary
  disorder that leads to unwarranted accumulation
  of copper in crucial organs such as the liver,
  brain etc. The patient starts to accumulate
  copper from birth but diagnosis tends not to
  occur only in the later ages. The primary signs
  of Wilsons disease become prominent usually
  between the ages of 12 and 23 years.
• Wilsons disease is caused by the mutation of a
  gene named ATP7B. Absent or reduced function of
  ATP7B protein leads to reduced elimination of
  copper into the bile. Wilsons disease is
  inherited as an autosomal recessive trait, which
  means that in order to develop the disease one
  must inherit two procreations of the defective
  gene, one from each parent. If a person receives
  only one abnormal gene from either of the
  parents, he/she is not likely to get affected by
  the Wilsons disease. Wilsons disease may be
  difficult to primarily diagnose as the symptoms
  are alike to other health issues like heavy metal
  poisoning, hepatitis C, and cerebral palsy.
• The important factors that are anticipated to
  drive the market include rising prices of
  chelators in the US, rising attractiveness of
  orphan drugs market, increasing global healthcare
  expenditure as well as spending on medicines. The
  noteworthy trends in the market include falling
  number of prescriptions for Wilsons disease, and
  the development of gene therapy as a potential
  cure for the disease. However, the market is
  confronted by crucial challenges such as
  under-diagnosis of the disease, lack of safety in
  treatments, poor compliance to current treatments
  and unmet efficacy needs.
• This report provides a wide-ranging study of
  global Wilsons disease market and also its key
  regional markets such as the US and Europe.
  Furthermore, market dynamics such as key trends
  and development and challenges are analyzed in
  depth. The global Wilsons disease industry is
  highly competitive consisting of several large
  corporations. The competitive landscape of the
  respective market, along with the company
  profiles of the leading players are also
  discussed in detail.

3
Though it is known that Wilsons disease is a
rare condition, the prevalence of this disease is
limited also because the occurrence of this
condition is highly underdiagnosed
Global Orphan Drugs Market Revenue Actuals
(2012-2015)

• The global orphan drugs market revenue has been
  growing at a CAGR of xx during the period
  spanning 2012-2015. For the year 2015, the global
  orphan drugs revenue was noted to be US...
  billion which has increased from US.. billion in
  the year 2014.
• It is noted that the prevalence of Wilsons
  disease is the largest in Europe with nearly
  persons being affected by it in the year 2015,
  followed by the US with . persons affected by
  Wilsons disease.
• In terms of treatment among newly diagnosed
  patients, it is noted that the market remains
  highly skewed towards D-penicillamine, which
  recorded a share of xx of the total market in
  the year 2015

Wilsons Disease Prevalence by Region (2015)
Wilsons Disease Market by Treatment New
Patients (2015)
4
Europe has the highest prevalence of Wilsons
disease in the world
Europe Wilsons Disease Prevalence Forecast
(2015-2020)

• The number of persons affected with Wilsons
  disease in Europe in the year 2015, was noted to
  be persons. It is forecasted that the
  prevalence count will reach a sum of .. persons
  by the end of the year 2020.
• It is noted that in the year 2015, zinc salts
  constituted xx of the total market while
  chelators constituted nearly xx of the total
  market in the same period.
• The number of Wilsons disease patients treated
  with zinc in the year 2015 is noted to be .
  persons. It is forecasted that the number of
  patients treated with zinc will rise at a CAGR of
  xx over the period 2015-2020, attaining a total
  of . persons by the end of the year 2020.

Europe Wilsons Disease Market by Treatment (2015)
Europe Wilsons Disease Patients Treated with
Zinc - Forecast (2015-2020)
5
Even though the number of prescriptions for
chelators has been declining over the past few
years in the US, the continuing rise in the
prices of chelators is set to make the market
revenue grow over the forthcoming years
The US Wilsons Disease Prevalence Forecast
(2015-2020)

• The prevalence of Wilsons disease is the second
  largest in the US with nearly persons affected
  by it in the year 2015. It is forecasted that the
  prevalence of this disease will grow rather
  gradually at a CAGR of xx over the forthcoming
  period spanning 2015-2020.
• It is forecasted that the market revenue of
  copper chelators for Wilsons disease in the US
  will grow at a CAGR of xx over the period
  spanning 2016-2020, attaining total revenue of
  US.... million by the end of 2020.
• The total number of patients treated with
  chelators in 2015, was recorded to be .. persons
  in the US. It is forecasted that the number of
  patients treated with chelators will attain a sum
  of . persons by the end of 2020.

The US Chelators Market Revenue Forecast
(2016-2020)
The US Wilsons Disease Patients Treated with
Chelators Forecast (2015-2020)
6
Contact Us
View Report Details
These are abridged and sanitized sample pages
from the comprehensive report on the Global
Wilson Disease Market . To know more about this
report or for any customized research
requirement, please contact the following
Koncept Analytics CS-36, Second Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T.
91-120-4130959 C 91-9811715635
vikas_at_konceptanalytics.com
Vikas Gupta BD Manager
www.konceptanalytics.com